Do analysts prefer ANEB or FBLG?

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, ANEB or FBLG?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is ANEB or FBLG more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% FibroBiologics N/A -767.07% -195.56%

Do analysts rate QCLS or FBLG?

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, QCLS or FBLG?

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is QCLS or FBLG more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% FibroBiologics N/A -767.07% -195.56%

Do analysts recommend MAAQ or FBLG?

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Mana Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, MAAQ or FBLG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mana Capital Acquisition N/A N/A N/A N/A N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is MAAQ or FBLG more profitable?

Mana Capital Acquisition's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Mana Capital Acquisition N/A N/A N/A FibroBiologics N/A -767.07% -195.56%

Do analysts prefer AIMD or FBLG?

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is AIMD or FBLG more profitable?

FibroBiologics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% FibroBiologics N/A -767.07% -195.56%

Is FBLG or APLT more profitable?

Applied Therapeutics' return on equity of -340.84% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% Applied Therapeutics N/A -340.84% -175.00%

FibroBiologics (FBLG) Competitors

$0.74 -0.02 (-3.17%)

As of 03:55 PM Eastern

Compare

FBLG vs. ANEB, QCLS, MAAQ, AIMD, and APLT

Should you buy FibroBiologics stock or one of its competitors? MarketBeat compares FibroBiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FibroBiologics include Anebulo Pharmaceuticals (ANEB), Mymd Pharmaceuticals (QCLS), Mana Capital Acquisition (MAAQ), Ainos (AIMD), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.

How does FibroBiologics compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anebulo Pharmaceuticals' return on equity of -74.57% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
FibroBiologics	N/A	-767.07%	-195.56%

In the previous week, FibroBiologics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
FibroBiologics	Neutral

Anebulo Pharmaceuticals has a beta of -1.88, indicating that its share price is 288% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Anebulo Pharmaceuticals and FibroBiologics tied by winning 6 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Mymd Pharmaceuticals?

Mymd Pharmaceuticals (NASDAQ:QCLS) and FibroBiologics (NASDAQ:FBLG) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

Mymd Pharmaceuticals' return on equity of -76.40% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
FibroBiologics	N/A	-767.07%	-195.56%

Mymd Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, FibroBiologics had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
FibroBiologics	Neutral

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FibroBiologics beats Mymd Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and FibroBiologics (NASDAQ:FBLG) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Mana Capital Acquisition's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
FibroBiologics	N/A	-767.07%	-195.56%

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Mana Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, FibroBiologics had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score.

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
FibroBiologics	Neutral

68.4% of Mana Capital Acquisition shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

FibroBiologics beats Mana Capital Acquisition on 5 of the 8 factors compared between the two stocks.

How does FibroBiologics compare to Ainos?

Ainos (NASDAQ:AIMD) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 9,832.89%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ainos has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

FibroBiologics has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
FibroBiologics	N/A	-767.07%	-195.56%

Ainos has higher revenue and earnings than FibroBiologics. Ainos is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	128.94	-$14.77M	-$2.89	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, FibroBiologics had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for Ainos. Ainos' average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score.

Company	Overall Sentiment
Ainos	Neutral
FibroBiologics	Neutral

Summary

Ainos and FibroBiologics tied by winning 6 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Applied Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, FibroBiologics had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for Applied Therapeutics. FibroBiologics' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
FibroBiologics	Neutral
Applied Therapeutics	Neutral

98.3% of Applied Therapeutics shares are held by institutional investors. 9.3% of FibroBiologics shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

FibroBiologics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

FibroBiologics has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

FibroBiologics currently has a consensus price target of $74.00, suggesting a potential upside of 9,832.89%. Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe FibroBiologics is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Applied Therapeutics' return on equity of -340.84% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Applied Therapeutics	N/A	-340.84%	-175.00%

Summary

FibroBiologics beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.88M	$3.55B	$6.67B	$12.22B
Dividend Yield	N/A	2.28%	2.68%	5.89%
P/E Ratio	-0.11	21.23	25.73	24.02
Price / Sales	N/A	330.17	588.41	124.95
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.40	7.99	10.51	6.33
Net Income	-$18.65M	$23.91M	$3.57B	$337.11M
7 Day Performance	-3.27%	1.55%	0.87%	-1.12%
1 Month Performance	-29.05%	1.87%	0.70%	0.46%
1 Year Performance	-94.83%	56.86%	30.92%	29.16%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.5639 of 5 stars	$0.75 -3.2%	$74.00 +9,832.9%	-94.8%	$3.88M	N/A	N/A	10
ANEB Anebulo Pharmaceuticals	N/A	$0.40 +13.0%	N/A	-73.7%	$16.14M	N/A	N/A	4
QCLS Mymd Pharmaceuticals	1.0585 of 5 stars	$3.86 -3.3%	N/A	N/A	$16.10M	N/A	N/A	6	Gap Down
MAAQ Mana Capital Acquisition	N/A	$1.97 -0.5%	N/A	-40.5%	$16.01M	N/A	N/A	1	Gap Down
AIMD Ainos	0.3823 of 5 stars	$1.87 +0.5%	N/A	-27.7%	$15.94M	$18.11K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. ANEB, QCLS, MAAQ, AIMD, and APLT

How does FibroBiologics compare to Anebulo Pharmaceuticals?

Summary

How does FibroBiologics compare to Mymd Pharmaceuticals?

Summary

How does FibroBiologics compare to Mana Capital Acquisition?

Summary

How does FibroBiologics compare to Ainos?

Summary

How does FibroBiologics compare to Applied Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. ANEB, QCLS, MAAQ, AIMD, and APLT

How does FibroBiologics compare to Anebulo Pharmaceuticals?

Do analysts prefer ANEB or FBLG?

Is ANEB or FBLG more profitable?

Does the media prefer ANEB or FBLG?

Which has more volatility & risk, ANEB or FBLG?

Which has better earnings & valuation, ANEB or FBLG?

Do insiders & institutionals have more ownership in ANEB or FBLG?

Summary

How does FibroBiologics compare to Mymd Pharmaceuticals?

Which has better earnings & valuation, QCLS or FBLG?

Is QCLS or FBLG more profitable?

Which has more risk & volatility, QCLS or FBLG?

Does the media prefer QCLS or FBLG?

Do analysts rate QCLS or FBLG?

Do institutionals and insiders hold more shares of QCLS or FBLG?

Summary

How does FibroBiologics compare to Mana Capital Acquisition?

Is MAAQ or FBLG more profitable?

Do analysts recommend MAAQ or FBLG?

Which has preferable earnings & valuation, MAAQ or FBLG?

Does the media prefer MAAQ or FBLG?

Do institutionals and insiders believe in MAAQ or FBLG?

Summary

How does FibroBiologics compare to Ainos?

Do analysts prefer AIMD or FBLG?

Which has more risk and volatility, AIMD or FBLG?

Is AIMD or FBLG more profitable?

Which has better valuation and earnings, AIMD or FBLG?

Does the media refer more to AIMD or FBLG?

Summary

How does FibroBiologics compare to Applied Therapeutics?

Does the media favor FBLG or APLT?

Do insiders and institutionals hold more shares of FBLG or APLT?

Which has more volatility & risk, FBLG or APLT?

Which has stronger earnings and valuation, FBLG or APLT?

Do analysts recommend FBLG or APLT?

Is FBLG or APLT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools